46 results
8-K
EX-99.1
ANEB
Anebulo Pharmaceuticals Inc
13 Feb 24
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024
4:15pm
continued. “Despite the high tolerability of cannabis in the majority of users, a significant number of users who develop ACI may experience moderate
PRE 14A
hnek 4y2vsrfozw
19 Oct 23
Preliminary proxy
5:18pm
DEFR14A
4ame2g9bv 6w
25 Oct 22
Revised proxy
5:27pm
8-K
EX-3.1
rchj 5tm0
13 Oct 22
Amendments to Articles of Incorporation or Bylaws
4:05pm
8-K
EX-4.1
x85yncl5x19npyb9f
29 Sep 22
Anebulo Pharmaceuticals Announces $6.6 million Private Placement Financing
4:05pm